TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain MetastasesRachel A. Freedman, Nancy U. Lin, Rebecca Gelman et al.|Journal of Clinical Oncology|2019Cited by 341
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarkerErica L. Mayer, Eric P. Winer, Lisa A. Carey et al.|Annals of Oncology|2020Cited by 81
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022Rachel A. Freedman, Nancy U. Lin, Rebecca Gelman et al.|Clinical Breast Cancer|2019Cited by 28